2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMORecruiting
To assess to efficacy of locally applied tacrolimus suppositories compared to beclomethason suppositories in patients with recurrent or refactory ulcerative proctitis.